Introduction
============

IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide and the leading cause of the end-stage renal disease (ESRD) in young adults.^\[[@R1]\]^ About 30% of IgAN patients progressed to ESRD in about 20 to 30 years. Therefore, it is critical to identify modifiable risk factors to slow down disease progression and improve the clinical outcomes of IgAN.

Elevated homocysteine is frequently observed in patients with chronic kidney disease (CKD) ^\[[@R2]\]^ and occurs almost uniformly in patients with ESRD.^\[[@R3]\]^ Randomized controlled trial (RCT) suggested that folic acid therapy can significantly delay the progression of CKD among patients with mild-to-moderate CKD.^\[[@R4]\]^ IgAN is the most common form of glomerulonephritis and the leading cause of ESRD. However, as far as we know, there is only one small retrospective study suggesting that elevated levels of homocysteine were associated with intrarenal arterial lesions and poor renal outcome in IgAN patients.^\[[@R5]\]^ As potential bias is inherent to cohort or observational studies. It is a key challenge to detect whether the association between homocysteine and IgAN is reverse causal^\[[@R6]\]^ or is confounded by other factors.^\[[@R7],[@R8]\]^ The answers to these questions have clinical importance, as it has been reported that supplementation with folate can reduce homocysteine levels by 25%, and that treatment with vitamin B12 can reduce homocysteine levels by an additional 7%.^\[[@R9]\]^

Normally, high quality and well-powered RCTs are required to establish a causal relationship. However, conventional RCTs are time-consuming and costly. In the absence of large and well-designed RCTs, the Mendelian randomization (MR) approach provides a timely opportunity to test the causal effects of homocysteine on clinical-pathologic manifestations of IgAN. In essence, MR exploits the random allocation of genetic variants at conception; therefore, less susceptible to confounding than traditional observational studies. It is at the interface of experimental and observational studies and can be used to obtain evidence in support of a potential causal effect or of potential targets of interventions.^\[[@R10]\]^ The missense mutation C677T (rs1801133) in the human gene methylenetetrahydrofolate reductase (*MTHFR*), which encodes a key enzyme for homocysteine metabolism, was reported to have the most consistent effect on plasma homocysteine in Europeans.^\[[@R11]\]^ It is predicted to substitute a valine residue for an alanine (A222V), which is likely to reduce the enzyme\'s activity by 50%, resulting in high plasma levels of homocysteine. Considering that the risk allele T of *MTHFR* C677T (rs1801133) is especially high in Chinese compared with Europeans,^\[[@R12]\]^ the genetic variant *MTHFR* C677T (rs1801133) could be an ideal instrument for testing whether elevated plasma homocysteine is causally related to IgAN in Chinese.

Thus, the present study was designed to answer the following three questions: (1) Whether plasma homocysteine is elevated and associated with clinical-pathologic manifestations of patients with IgAN? (2) Whether *MTHFR* C677T (rs1801133) is associated with plasma homocysteine in IgAN patients? (3) Whether the associations of plasma homocysteine with any clinical-pathologic manifestations of IgAN patients are causal?

Methods
=======

Ethical approval
----------------

The study and consent procedures were performed in accordance with the *Declaration of Helsinki.* This study was approved by the Ethics Committee of Peking University First Hospital (No. 2013\[548\]) and written informed consent was provided by all participants.

Participants and data collection
--------------------------------

The study design is shown in Figure [1](#F1){ref-type="fig"}. For observational analysis, to compare the plasma levels of homocysteine between IgAN patients and controls, we recruited 108 IgAN patients (male 58/108, 53.70%; mean age 37.02 ± 11.04 years), 30 lupus nephritis (LN) patients (male 7/30, 23.33%; mean age 35.57 ± 14.17 years), 50 minimal change disease (MCD) patients (male 24/50, 48.00%; mean age 36.80 ± 16.36 years), and 206 healthy controls from April 2014 to April 2015. Their plasma homocysteine was detected and the clinical-pathologic manifestations of the patients were collected. For MR analysis, the relationship between *MTHFR* C677T (rs1801133) and homocysteine was estimated in the 108 IgAN patients. To detect the associations of *MTHFR* C677T (rs1801133) with clinical-pathologic manifestations, 1686 IgAN patients (male 888/1686, 52.67%; mean age 33.77 ± 11.77 years) \[Table [1](#T1){ref-type="table"}\] were included.

Figure 1Study design of the work. For observational analysis, we recruited 108 IgAN patients, 30 LN patients, 50 MCD patients, and 206 healthy controls. Their plasma homocysteine was detected and the clinical-pathologic manifestations of the patients were collected. For MR analysis, the relationship between *MTHFR* C677T (rs1801133) and homocysteine was estimated in the 108 IgAN patients. To detect the associations of *MTHFR* C677T (rs1801133) with clinical-pathologic manifestations, 1686 IgAN patients were included. The effects of homocysteine on the outcomes were established using the "Wald estimation." ANOVA: Analysis of variance; IgAN: IgA nephropathy; LN: Lupus nephritis; MCD: Minimal change disease; MR: Mendelian randomization; MTHFR: Methylenetetrahydrofolate reductase.

###### 

Baseline clinical-pathologic manifestations of the 1686 patients with IgA nephropathy.
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Patients with IgAN, LN, and MCD were diagnosed by renal biopsy. All renal-biopsy specimens were reviewed and graded by an independent pathologist who was blinded to patient information. Clinical-pathologic manifestations of the patients, including age, sex, serum creatinine, estimated glomerular filtration rate (eGFR, calculated using the Chronic Kidney Disease-Epidemiology Collaboration equation), urinary protein excretion, systolic/diastolic blood pressure, serum IgA, serum IgG, serum IgM, serum C3, IgA deposition, and C3 deposition were collected. The histological lesions for IgAN were also classified as proposed by the Oxford classification system, including mesangial hypercellularity (M), endocapillary proliferation (E), segmental sclerosis (S), and tubular atrophy and interstitial fibrosis (T).

Plasma homocysteine detection and grouping
------------------------------------------

Plasma homocysteine was measured using the ARCHITECT Homocysteine Reagent Kit (The Technology Park, Dundee, UK). It was divided into two groups by the cut off value of 10 μmol/L and into four equal groups according to the quartiles (Group 1: \<13.01 μmol/L; Group 2: 13.01--18.31 μmol/L; Group 3: 18.32--25.87 μmol/L; and Group 4: \>25.87 μmol/L).

Genetic instrument selection and genotyping
-------------------------------------------

According to previous studies, we selected the missense variant *MTHFR* C677T (rs1801133) with the most consistent effect on plasma homocysteine as the genetic instrument.^\[[@R11]\]^ It was genotyped using TaqMan allele discrimination assays (Applied Biosystems, Foster City, CA, USA) according to the manufacturer\'s instructions.

Statistical analyses
--------------------

For observational analysis, continuous variables were tested for normal distribution using the Kolmogorov-Smirnov test. Variables with a normal distribution were expressed as means ± standard deviations, the independent-samples *t*-test (two groups) or analysis of variance (analysis of variance, multiple groups) was used for analyses. Non-normally distributed variables were expressed as medians and interquartile range and were analyzed using the Mann-Whitney *U* test (two groups) or the Kruskal-Wallis *H* test (multiple groups). Categorical variables were presented as *n* (%) and were analyzed using the Chi-square test.

For two-sample MR analysis, we first assessed the association of *MTHFR* C677T (rs1801133) with plasma homocysteine levels using linear regression by adjusting for age and sex, assuming a linear effect of *MTHFR* C677T (rs1801133) per additional allele-T in the 108 IgAN patients. The strength of the association was assessed by using Cragg-Donald F statistics; values greater than 10 were regarded as useful for MR analysis.^\[[@R13]\]^ Then, the associations of *MTHFR* C677T (rs1801133) with clinical-pathologic manifestations of IgAN were analyzed using logistic or linear regression by adjusting for age and sex, assuming a linear effect of *MTHFR* C677T (rs1801133) per additional allele-T in the 1686 IgAN patients. Finally, the effects of homocysteine on the clinical-pathologic manifestations of IgAN patients were estimated using the "Wald estimation."^\[[@R14]\]^

All analyses were performed using STATA software, version 13.1 (STATA Corporation, College Station, TX, USA). A two-tailed *P* \< 0.05 was considered statistically significant.

Results
=======

Baseline clinical and pathologic characteristics
------------------------------------------------

In total, 108 IgAN patients, 30 LN patients, 50 MCD patients, and 206 healthy controls were recruited. Except for age and blood pressure, all the other parameters varied across three groups of patients, representing their disease characteristics. There was a lower male rate in LN patients (53.70% in IgAN *vs.* 23.33% in LN *vs.* 48.00% in MCD, *χ*^*2*^ = 8.70, *P* = 0.01), higher levels of proteinuria in patients with LN and MCD (median: 1.47 g/d in IgAN *vs.* 4.65 g/d in LN *vs.* 7.17g/d in MCD, *χ*^*2*^ = 35.99, *P* \< 0.01), higher serum levels of IgA in IgAN (median: 3.12 g/L in IgAN *vs.* 2.56 g/L in LN *vs.* 2.15 g/L in MCD, *χ*^*2*^ = 15.95, *P* \< 0.01), and more intensive IgA deposition in IgAN (87.77% \>2+ in IgAN *vs.* 32.00% \>2+ in LN *vs.* 7.5% \>2+, *χ*^*2*^ = 122.23, *P* \< 0.01). Oxford M1, E1, S1, T1/2 were found in 96.23%, 29.25%, 62.26%, and 66.98% of IgAN patients, respectively \[Table [2](#T2){ref-type="table"}\].

###### 

Baseline clinical-pathologic manifestations of patients with IgA nephropathy, lupus nephritis, and minimal change disease.
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Plasma levels of homocysteine in IgAN patients and controls
-----------------------------------------------------------

Approximately 93.52% (101/108) patients with IgAN showed elevated plasma homocysteine (\>10 μmol/L). Plasma homocysteine in IgAN patients were significantly higher than those in patients with MCD (median: 18.32 *vs.* 11.15 μmol/L, *Z* = −5.29, *P* \< 0.01) and in healthy controls (median: 18.32 *vs.* 10.00 μmol/L, *Z* = −8.76, *P* \< 0.01), but comparable with those in LN patients (median: 18.32 *vs.* 14.50 μmol/L, *Z* = −1.32, *P* = 0.19) \[Figure [2](#F2){ref-type="fig"}\].

Figure 2Comparison of plasma homocysteine in IgAN patients, LN patients, MCD patients, and healthy controls. The majority of patients with IgAN showed elevated plasma homocysteine (\>10 μmol/L). Plasma homocysteine in IgAN patients was significantly higher than those in patients with MCD and in healthy controls but comparable with those in LN patients. IgAN: IgA nephropathy; LN: Lupus nephritis; MCD: Minimal change disease.

Observational analysis
----------------------

### Associations of plasma homocysteine with clinical-pathologic manifestations of IgAN patients

When the IgAN patients were divided into four groups by quartiles of plasma homocysteine, plasma homocysteine was positively associated with serum creatinine (*P* \< 0.01), systolic blood pressure (*P* \< 0.01), diastolic blood pressure (*P* ≤ 0.01), pathologic T lesion (*P* \< 0.01), and negatively associated with eGFR (*P* \< 0.01) \[Table [3](#T3){ref-type="table"}\]. Similar association results were observed when the patients were divided by 10 μmol/L \[Table [4](#T4){ref-type="table"}\]. Thus we further detect whether plasma homocysteine was causally associated with these clinical-pathologic manifestations.

###### 

Baseline clinical-pathologic manifestations of IgA nephropathy patients in four groups defined by quartiles of plasma homocysteine.
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###### 

Baseline clinical-pathologic manifestations of IgA nephropathy patients in sub-groups defined by plasma homocysteine.
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MR analysis
-----------

### Association of *MTHFR C677T* (rs1801133) with plasma homocysteine of IgAN patients

The patients with genotype TT of *MTHFR* C677T (rs1801133) showed higher plasma levels of homocysteine than patients with genotypes of CT and CC (median: 25.93 *vs.* 17.07 *vs.* 18.17 μmol/L, *χ*^*2*^ = 8.86, *P* = 0.01) \[Figure [3](#F3){ref-type="fig"}\]. The effect of each *MTHFR* C677T (rs1801133) T allele on homocysteine levels after controlling age and sex was *β* = 7.12 (*P* \< 0.01) \[Table [5](#T5){ref-type="table"}\].

Figure 3Comparison of plasma homocysteine according to rs1801133 genotypes in IgA nephropathy patients. The patients with the risk genotype TT of *MTHFR* C677T (rs1801133) showed higher plasma levels of homocysteine than patients with genotypes of CT and CC. *MTHFR:* Methylenetetrahydrofolate reductase.

###### 

Mendelian randomization analysis using rs1801133 as instrument.
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### Associations of *MTHFR C677T* (rs1801133) with clinical-pathologic manifestations of IgAN patients

The associations of *MTHFR* C677T (rs1801133) with clinical-pathologic characteristics, including serum creatinine, eGFR, proteinuria, systolic blood pressure, diastolic blood pressure, and Oxford MEST score, were shown in Table [5](#T5){ref-type="table"}. Regression analysis after adjusting for age and sex suggested that patients with the risk allele T tended to have higher serum creatinine (*β* = 5.44, *P* = 0.03), higher systolic blood pressure (*β* = 1.84, *P* = 0.02), higher diastolic blood pressure (*β* = 1.45, *P* = 0.02), and a higher rate of T lesion (*β* = 0.08, *P* = 0.01) \[Table [5](#T5){ref-type="table"}\].

### Causal effect of plasma homocysteine with clinical-pathologic manifestations of IgAN patients

After combining two estimates of gene-homocysteine and gene-disease phenotype, our MR estimates showed causal effects of homocysteine on serum creatine (*β* = 0.76, *P* = 2.40 × 10^−2^), higher systolic blood pressure (*β* = 0.26, *P* = 0.02), higher diastolic blood pressure (*β* = 0.20, *P* = 0.01), and higher proportion of T lesion (*β* = 0.01, *P* = 0.01) in IgAN.

Discussion
==========

In this very first observational and MR study, we detected the associations between plasma homocysteine with clinical-pathologic parameters of IgAN and tested whether these associations were causal using two-sample MR analysis. We found that plasma homocysteine is commonly elevated in IgAN (\>90% patients). It was significantly associated with sex, serum creatinine, eGFR, blood pressure, and T lesion, but not associated with neither serum IgA nor IgA deposition in renal biopsy. The missense variant *MTHFR* C677T (rs1801133) is associated with plasma homocysteine in Chinese. Using the two-sample MR method, the causal effects of plasma homocysteine and serum creatinine, blood pressures, and T lesion were confirmed, suggesting that plasma homocysteine would be a candidate modifiable risk factor for IgAN.

Numbers of studies have suggested the vascular damage effects of homocysteine and its association with cardiovascular disease in ESRD.^\[[@R15],[@R16]\]^ Homocysteine has a detrimental effect on the vascular wall by inducing the expression of chemokines (interleukin \[IL\]-8 and/or monocyte chemotactic protein 1 \[MCP-1\]) and their receptors in vascular cells and monocytes.^\[[@R17],[@R18]\]^ Moreover, it could also stimulate the production of many other cytokines and pro-inflammatory molecules, including IL-1β,^\[[@R19]\]^ IL-12,^\[[@R19]\]^ IL-6,^\[[@R19]--[@R21]\]^ C-reactive protein,^\[[@R20]\]^ IL-1 receptor antagonist,^\[[@R21]\]^ IL-18,^\[[@R22]\]^ adhesion molecules (P-selectin, E-selectin, intercellular adhesion molecules 1),^\[[@R23]\]^ and metalloproteinases.^\[[@R24]\]^ These immuno- and inflammatory responses caused by homocysteine could induce a series of pathological processes, including blood pressure elevation and blood vessel proliferation.^\[[@R25]\]^ In the current study, our observational analysis suggested the associations between homocysteine and sex, systolic blood pressure, diastolic blood pressure, serum creatinine, eGFR, and T lesion. Since homocysteine is reported reversely affected by eGFR levels and other confounders, such as sex, baseline folate, and smoking status.^\[[@R26]\]^ We use the missense variant *MTHFR* C677T (rs1801133), which showed consistent effects on homocysteine levels in genome-wide association studies and experimental studies,^\[[@R11]\]^ as the genetic instrument to detect the causal role of homocysteine on clinical-pathologic manifestations of IgAN patients using MR method. We first validated the significant association of *MTHFR* C677T (rs1801133) with plasma homocysteine in Chinese. Then, using the two-sample MR method, the positive associations between homocysteine and systolic blood pressure, diastolic blood pressure, serum creatinine, and T lesion were confirmed. Although the genetically elevated homocysteine is negatively associated with eGFR levels, no statistical significance was observed, which might due to the relatively small sample size in our study. Overall, our results suggested that renal insufficiency could result in elevated homocysteine, which in turn deteriorate renal function through elevating blood pressure and inducing T lesion in IgAN.

Six criteria used in the MR approach must be considered.^\[[@R27]\]^ (1) Suitable genetic variants are required to study modifiable exposures of interest. The missense variant *MTHFR* C677T (rs1801133) affected enzyme activity was considered to have the most consistent effect on plasma homocysteine concentrations.^\[[@R11]\]^ (2) Reliable genotype-intermediate-phenotype and genotype-disease associations can be established. Here, we showed that the risk allele T of *MTHFR* C677T (rs1801133) was positively associated with plasma homocysteine and clinical-pathologic manifestations of IgAN patients. (3) There is no confounding of these relationships. Only the variant with the most consistent effect on plasma homocysteine was chosen in this study. (4) There are no pleiotropic effects of the genetic variants of interest. Currently, we are not aware of any association between *MTHFR* C677T (rs1801133) and a phenotype besides changes in homocysteine level that could influence the risk of IgAN. (5) There is no compensation from other genes during development. Although this sort of compensation is genetically difficult to assess, many polymorphisms modifying the metabolism of folate or vitamin B12 (which can affect homocysteine plasma concentrations) have been identified. However, *MTHFR* C677T (rs1801133) was regarded to have the most consistent effect while the others showed no major effect on homocysteine concentrations.^\[[@R11]\]^ (6) Subject population does not differ between cases and controls. The present study was conducted using a large, ethnically homogenous patients of Chinese Han descent, and effectively can exclude admixture effects. Thus, the classical limitations of MR do not appear to be a major problem in the study.

However, there are still limitations in the present study. Notably, this study is limited to the single instrument (*MTHFR* C677T) of homocysteine, even it was reported to have the most consistent effect on plasma homocysteine and was widely used in RCTs ^\[[@R28]\]^ and MR studies.^\[[@R29],[@R30]\]^ In addition, as in most epidemiological studies, MR assumes a linear relation between homocysteine and clinical manifestations, which might not invariably be the case. In the future, RCTs are required to detect the benefits of homocysteine-lowering in IgAN patients.

In summary, plasma homocysteine is commonly elevated in patients with IgAN. By observational and MR analysis, consistent results were detected for the associations between homocysteine and serum creatinine, blood pressures, and pathogenic T lesion in IgAN. Since high levels of homocysteine is commonly seen in IgAN patients and folic acid is an inexpensive and important contributor to lowering blood homocysteine, our results provide clues for targeting homocysteine in preventing the disease progression of IgAN.
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